Ifetroban - Cumberland Pharmaceuticals
Alternative Names: BMS 18029; BMS 180291; BMS 180291A; BMS-180291-02; Boxaban; CPI 211; Dyscorban; Hepatoren; Portaban; VasculanLatest Information Update: 09 Aug 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals; Vanderbilt-Ingram Cancer Center
- Class Antiasthmatics; Antifibrotics; Antihypertensives; Antineoplastics; Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Skin disorder therapies; Small molecules
- Mechanism of Action Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Cardiomyopathies; Cardiovascular disorders; Hepatorenal syndrome; Idiopathic pulmonary fibrosis; Portal hypertension; Solid tumours; Systemic scleroderma
- Preclinical Interstitial lung diseases
- Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis
Most Recent Events
- 06 Aug 2024 Cumberland Pharmaceuticals expects to hear back from the US FDA on orphan drug designation and rare pediatric disease designation application for Duchenne Muscular Dystrophy this year
- 31 Jan 2024 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (PO) (NCT05571059)
- 08 Nov 2023 US FDA approves IND application for Ifetroban in Idiopathic Pulmonary Fibrosis